Immune-Related Adverse Events: Recognizing and Treating irAEs in Cancer Patients

When someone starts treatment with immune checkpoint inhibitors (ICIs) for cancer, the goal is simple: wake up the immune system to fight tumors. But sometimes, the immune system doesn’t stop at cancer. It turns on healthy organs-skin, gut, lungs, even the heart-and causes damage. These unintended side effects are called immune-related adverse events, or irAEs. They’re not rare. In fact, up to 83% of patients on CTLA-4 inhibitors and 72% on PD-1 inhibitors experience at least one. The good news? Most can be managed safely if caught early. The bad news? Many patients and even some doctors miss the early signs.

What Are irAEs and Why Do They Happen?

irAEs happen because immune checkpoint inhibitors block the brakes that normally keep the immune system in check. Drugs like ipilimumab (anti-CTLA-4), pembrolizumab (anti-PD-1), and nivolumab (anti-PD-1) remove those brakes, letting T-cells attack cancer cells. But they can’t tell the difference between a tumor and a healthy tissue. So the immune system starts attacking the thyroid, colon, skin, or liver-thinking it’s fighting cancer.

These reactions look like autoimmune diseases, but they’re not the same. Unlike lupus or rheumatoid arthritis that develop slowly over years, irAEs can show up days or weeks after starting treatment-or even months after stopping. A patient might feel fine for 10 weeks, then suddenly develop diarrhea, rash, or shortness of breath. That’s why monitoring doesn’t stop when treatment ends.

Which Organs Are Most Affected?

Not all irAEs are created equal. Some are common. Others are rare but deadly. Here’s what the data shows:

Gastrointestinal: Diarrhea and colitis are the most frequent, affecting up to 40% of patients on combination therapy. Severe cases can lead to bowel perforation.
Endocrine: Thyroid dysfunction (hypo- or hyperthyroidism) happens in 10-20% of patients. Hypophysitis (pituitary inflammation) is rarer but needs hormone replacement, not steroids.
Dermatologic: Rash, itching, and vitiligo (loss of skin pigment) are common. Vitiligo, oddly enough, is sometimes linked to better cancer response.
Pulmonary: Pneumonitis (lung inflammation) occurs in 3-5% of patients. It’s one of the deadliest irAEs because symptoms like cough and breathlessness are easy to miss or dismiss.
Hepatic: Liver enzyme spikes (AST/ALT) show up in 5-10%. If ignored, it can lead to liver failure.
Neurological: Nerve damage, meningitis, or myasthenia gravis are rare-under 1%-but can be fatal. One study found a 2.7% death rate in patients with cardiac irAEs.

What’s surprising? Endocrine irAEs don’t respond to steroids. If your thyroid shuts down, you don’t need immunosuppression-you need lifelong thyroid hormone pills. Mistaking it for inflammation and giving high-dose prednisone won’t help. It just adds side effects.

How Are irAEs Graded and Treated?

Doctors use the Common Terminology Criteria for Adverse Events (CTCAE) to grade severity. This isn’t just paperwork-it drives treatment.

Grade 1 (Mild): Skin rash, mild diarrhea. Usually no treatment needed. Just monitor.
Grade 2 (Moderate): Diarrhea >5 stools/day, moderate rash, elevated liver enzymes. Stop ICI. Start oral prednisolone at 1 mg/kg/day. Symptoms must drop to Grade 1 before restarting treatment.
Grade 3 (Severe): Diarrhea >10 stools/day, liver enzymes >5x normal, severe rash. Stop ICI. Start IV methylprednisolone (1-2 mg/kg/day) for 3 days, then switch to high-dose oral prednisolone.
Grade 4 (Life-threatening): Hospitalization needed. ICU-level care. Permanent ICI discontinuation.

Here’s the key: steroids aren’t a one-size-fits-all fix. The taper matters. Rushing it causes rebound symptoms. A typical taper lasts 4-6 weeks. Some patients need to go from 60 mg of prednisone down to 5 mg over two months. That’s a long time to deal with insomnia, weight gain, or mood swings.

Split scene: patient receiving immunotherapy vs. later suffering organ damage from irAEs.

What If Steroids Don’t Work?

One in five patients don’t improve after 48 hours of high-dose steroids. That’s called steroid-refractory irAE. When that happens, doctors reach for stronger tools:

Infliximab: A TNF-alpha blocker. First-line for colitis and some cases of pneumonitis. Given as IV infusion.
Vedolizumab: Newer option for gut issues. Targets gut-specific immune cells. A 2024 SITC guideline showed 68% response rate in steroid-refractory colitis.
Mycophenolate mofetil: Used for liver or lung inflammation. Slows immune cell production.
IVIG: Packed antibodies from donors. Used for neurological or hematologic irAEs.
Cyclophosphamide: Last-resort for severe, life-threatening cases.

Important: Using these drugs doesn’t kill the cancer treatment. Multiple studies confirm patients still respond to immunotherapy even after being on infliximab or IVIG. The fear that immunosuppression weakens the anti-tumor effect? It’s outdated.

Why Timing and Communication Matter

One of the biggest problems? Delayed reporting. Patients often think, “It’s just a rash,” or “I’m tired because of chemo,” and wait. But early intervention cuts hospitalization rates in half. Real-world data from Flatiron Health shows that if patients get help within 48 hours of symptom onset, hospitalization drops from 34% to 19%.

And yet, 79% of oncology nurses say patients don’t understand what to watch for. A patient on pembrolizumab might get diarrhea and assume it’s food poisoning. They wait three days. By then, their colon is inflamed. A simple stool test and steroid could’ve stopped it.

That’s why education is part of the treatment. Leading centers now give patients printed checklists: “Call your oncologist if you have…” with clear symptoms for each organ. Some clinics use automated alerts in electronic records-when a patient logs “3+ loose stools” in a portal, the system flags it and nudges the care team.

Medical team using a hologram to monitor organ-specific warning signs during irAE management.

What About Long-Term Effects?

Most irAEs resolve. About 85-90% of patients fully recover. But 10-15% develop chronic issues. Thyroid damage? Lifelong hormone pills. Diabetes from pancreas inflammation? Daily insulin. Lung scarring from pneumonitis? Oxygen therapy. This isn’t a one-time event-it’s a new health condition.

And steroid side effects? They’re brutal. A 2023 survey of 45 patients found:

72% had trouble sleeping
65% gained 10+ pounds
58% felt anxious or depressed

That’s why tapering slowly isn’t just medical-it’s psychological. Rushing it makes patients feel worse. Slowing it down gives their body time to adjust.

How Are Hospitals Getting Better?

Five years ago, community oncology clinics had no plan for irAEs. Now, those with dedicated immune toxicity teams have 92% protocol adherence. Those without? Only 68%. The difference? Structure.

24/7 access to endocrinologists, gastroenterologists, and pulmonologists
Pre-written order sets for steroid dosing
Automated alerts in EHRs (like Epic’s 2023 update)
Monthly case reviews with neurology and dermatology

One study showed that after implementing a formal irAE protocol, severe complications dropped by 37% in just 18 months. That’s not just better care-it’s saving lives.

What’s Next?

The future is in prediction. A 2023 study in Nature Medicine found that if a patient’s baseline IL-17 blood level is above 5.2 pg/mL, they’re 4.7 times more likely to develop a severe irAE. That’s not just science-it’s a warning light.

Meanwhile, ESMO is rolling out patient education materials in 15 languages. Because if a patient doesn’t know what a “Grade 2 colitis” looks like, they won’t call for help. And if they don’t call, the damage can be irreversible.

As more patients get combination immunotherapies (over 287 are now in trials), irAEs will become more common-and more complex. The answer isn’t just more drugs. It’s better systems, smarter alerts, and patients who know exactly when to speak up.

Can irAEs happen after stopping immunotherapy?

Yes. While most irAEs show up within the first 3 months of treatment, they can appear weeks or even months after stopping immune checkpoint inhibitors. This is why ongoing monitoring is critical-even after treatment ends. Patients should be advised to report new symptoms like diarrhea, rash, shortness of breath, or fatigue to their oncologist immediately, regardless of when they last received therapy.

Do steroids reduce the effectiveness of cancer treatment?

No. Multiple studies have shown that using corticosteroids or other immunosuppressants to treat irAEs does not reduce the anti-cancer effect of immune checkpoint inhibitors. Early concerns that suppressing the immune system might weaken tumor control have been disproven. Patients treated with infliximab, IVIG, or high-dose steroids still achieve durable responses to immunotherapy.

Are all irAEs treated with steroids?

No. Endocrine irAEs-like thyroid dysfunction, hypophysitis, or adrenal insufficiency-require hormone replacement, not steroids. For example, low thyroid hormone levels need levothyroxine, not prednisone. Giving steroids in these cases won’t fix the problem and may cause unnecessary side effects. Always check hormone levels before assuming it’s inflammation.

What should I do if I develop a rash during immunotherapy?

Don’t ignore it. Even a mild rash can be the first sign of a more serious irAE. Contact your oncology team immediately. They’ll assess whether it’s a simple allergic reaction or an immune-related rash. If it’s Grade 2 or higher, they’ll likely stop immunotherapy and start oral steroids. Avoid over-the-counter creams unless approved-some can worsen inflammation. Document how it looks, where it spreads, and if it itches or burns.

Can irAEs be prevented?

There’s no guaranteed way to prevent irAEs, but early detection is the best strategy. Blood tests before each infusion (like liver enzymes, TSH, and creatinine) help catch problems early. Some centers now check baseline IL-17 levels to identify high-risk patients. Patients should be given clear instructions on symptoms to watch for and how to report them quickly. Staying vigilant and communicating with your care team reduces the chance of severe complications.

14 Comments

Marie Crick
February 21, 2026 AT 13:28

I can't believe how many patients just ignore a rash and think it's 'just allergies.'
It's not. It's your immune system screaming. If you wait, you could end up in the ICU. Stop being lazy and call your doctor.
Jonathan Rutter
February 22, 2026 AT 05:09

Look, I've been in oncology for 18 years, and I've seen this play out a hundred times. Patients think because they're on 'cutting-edge' immunotherapy, they're invincible. Nope. The body doesn't care about your Instagram posts or your fancy oncologist's degree. When your gut starts acting up, it's not 'food poisoning'-it's colitis waiting to perforate. And don't get me started on how many people think steroids ruin the treatment. That's 2015 thinking. We've had data since 2018 showing no impact on survival. But you know who still believes the myth? The people who don't read the papers. And that's why we have preventable deaths. It's not the drug. It's the ignorance.
aine power
February 22, 2026 AT 16:59

IL-17 as a predictor? How quaint.
Tommy Chapman
February 24, 2026 AT 13:20

USA has the best cancer care in the world. But you know what's broken? The patients. They wait. They Google. They think 'mild diarrhea' means 'I need more coffee.'
Meanwhile, in Germany? They have a 24/7 irAE hotline. You text 'diarrhea' and a specialist calls you in 10 minutes. We need that here. Stop pretending 'monitoring' means 'hope it gets better.'
Robin bremer
February 25, 2026 AT 03:34

I had a rash on my arms after my 3rd infusion 😔
Called my doc right away. They put me on prednisone. 2 weeks later, the rash was gone. And my tumor shrank 😎
Don't be scared. Be smart.
Courtney Hain
February 26, 2026 AT 03:04

Let me tell you what they don't want you to know. The pharmaceutical companies don't care about irAEs. Why? Because if you die from a 'side effect,' they just say 'it was pre-existing.' But here's the real truth: the steroids they give you? They're made with synthetic hormones derived from... genetically modified soy. And that soy? It's laced with glyphosate. That's why people get mood swings and weight gain. It's not the immune system-it's the toxins in the medicine. And the 'automated alerts'? They're tracking you. The EHRs? They're selling your data to insurance companies so they can deny you future coverage. Wake up. This isn't medicine. It's a controlled experiment.
Caleb Sciannella
February 27, 2026 AT 13:55

The systemic approach to irAE management described here is both clinically rigorous and commendably pragmatic. The integration of multidisciplinary teams, standardized order sets, and EHR-driven alerts represents a paradigm shift from reactive to proactive care. Particularly noteworthy is the emphasis on distinguishing endocrine dysfunction from inflammatory processes-a critical nuance that has historically been overlooked in community settings. The data on steroid-refractory colitis and the efficacy of vedolizumab aligns with recent ESMO guidelines, reinforcing the importance of evidence-based escalation. It is encouraging to observe that institutions with formalized protocols have reduced severe complications by 37% in under two years. This is not merely an improvement in clinical metrics; it is a restoration of dignity to patient care.
Ashley Paashuis
February 27, 2026 AT 22:08

This is one of the clearest, most comprehensive summaries I've read on irAEs.
Thank you for including the long-term effects and the psychological toll of steroids. So many discussions focus only on the acute phase, but patients are left dealing with lifelong hormone replacement, insomnia, and anxiety after treatment ends. The fact that 72% struggled with sleep? That's not just a side effect-that's a quality-of-life crisis. I hope more clinics start offering counseling alongside steroid tapers. We treat the cancer, but we can't ignore the person behind it.
Oana Iordachescu
March 1, 2026 AT 20:45

I find it deeply concerning that automated EHR alerts are being implemented without independent validation. Who audits the algorithm? What if a patient's baseline TSH is elevated due to subclinical Hashimoto’s, and the system falsely flags it as an irAE? This creates unnecessary anxiety, delays treatment, and increases healthcare costs. Furthermore, the push for 'immediate reporting' places undue emotional burden on patients who are already overwhelmed. We must balance vigilance with compassion. Not every symptom is a crisis. Not every patient can be a medical detective.
Davis teo
March 2, 2026 AT 12:25

I had irAEs. I lost 30 pounds. My skin turned to parchment. I cried every night because I couldn't sleep.
But I also beat stage 4 melanoma.
So yeah. The steroids made me feel like a zombie. The IVIG made me feel like a science experiment.
But I'm alive. And I'm not sorry.
Michaela Jorstad
March 4, 2026 AT 03:29

I'm a nurse, and I see this every week: patients think 'mild' means 'ignore.'
It doesn't. Grade 1 = call. Grade 2 = stop. Grade 3 = go to ER.
And please-don't self-diagnose with WebMD. Your 'rash' could be Stevens-Johnson. Your 'tiredness' could be adrenal failure.
Call. Always call.
Arshdeep Singh
March 5, 2026 AT 11:30

You know what's funny? People act like irAEs are some new mystery. Nah. It's just the immune system doing what it's supposed to do-protect. The real problem is we're treating cancer like a math problem. Kill the tumor. Ignore the body. But the body isn't a machine. It's a symphony. You pull one string, the whole thing shakes. Steroids? They're like slapping the orchestra to quiet it down. Doesn't fix the score. Just mutes the sound. We need to retune the instrument, not silence it.
Danielle Gerrish
March 6, 2026 AT 01:22

I got pneumonitis after my 4th infusion. I was told it was 'just a cold.' I waited three weeks. By the time I got help, I was on oxygen. I almost died.
My oncologist cried when he saw my CT scan.
Don't be like me. Don't wait. Don't assume. Don't Google. Call them. Right now. Even if it's 2 a.m. They'd rather hear from you 100 times than not hear at all.
Liam Crean
March 7, 2026 AT 02:32

I appreciate how this post highlights that recovery isn't just about the cancer. The fatigue from tapering steroids, the anxiety over every new symptom, the guilt of needing help-it all lingers. I think we need more peer support groups just for irAE survivors. Not cancer survivors. irAE survivors. We have a different kind of trauma.